CR20210493A - SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE - Google Patents

SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE

Info

Publication number
CR20210493A
CR20210493A CR20210493A CR20210493A CR20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A CR 20210493 A CR20210493 A CR 20210493A
Authority
CR
Costa Rica
Prior art keywords
pbmcs
immune response
biomolecules
modify
delivery
Prior art date
Application number
CR20210493A
Other languages
English (en)
Inventor
Armon R Sharei
Matthew Booty
Emrah Ilker Ozay
Scott Loughhead
Howard Bernstein
Kelan Hlavaty
Defne Yarar
Katarina Blagovic
Carolyne Kelly Smith
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of CR20210493A publication Critical patent/CR20210493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud proporciona células sanguíneas periféricas mononucleares (PBMCs) que comprenden un antígeno, métodos de producción de dichas PBMCs, y métodos de utilización de dichas PBMCs, tales como la modulación de una respuesta inmune en un individuo. En ciertas realizaciones, las PBMCs están acondicionadas al incubar la PBMC en presencia de un coadyuvante
CR20210493A 2019-02-28 2020-02-27 SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE CR20210493A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962812225P 2019-02-28 2019-02-28
EP19161964 2019-03-11
US201962841089P 2019-04-30 2019-04-30
US201962886799P 2019-08-14 2019-08-14
US201962933304P 2019-11-08 2019-11-08
US201962948732P 2019-12-16 2019-12-16
PCT/US2020/020194 WO2020176789A1 (en) 2019-02-28 2020-02-27 Delivery of biomolecules to pbmcs to modify an immune response

Publications (1)

Publication Number Publication Date
CR20210493A true CR20210493A (es) 2022-01-17

Family

ID=72238527

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210493A CR20210493A (es) 2019-02-28 2020-02-27 SUMINISTRO DE BIOMOLÉCULAS A PBMCs PARA MODIFICAR UNA RESPUESTA INMUNE

Country Status (19)

Country Link
US (2) US11692168B2 (es)
EP (1) EP3931309A4 (es)
JP (1) JP7610773B2 (es)
KR (1) KR20210134353A (es)
CN (1) CN114127267A (es)
AU (1) AU2020228648A1 (es)
BR (1) BR112021016903A2 (es)
CA (1) CA3131701A1 (es)
CL (1) CL2021002258A1 (es)
CO (1) CO2021012581A2 (es)
CR (1) CR20210493A (es)
IL (1) IL285809A (es)
MX (1) MX2021010320A (es)
PE (1) PE20220379A1 (es)
PH (1) PH12021500033A1 (es)
SG (1) SG11202109333SA (es)
TW (1) TWI904084B (es)
WO (1) WO2020176789A1 (es)
ZA (1) ZA202106308B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
RU2770492C2 (ru) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биологических молекул для индуцирования толерантности
MA52003A (fr) 2018-03-12 2021-01-20 Sqz Biotechnologies Co Procédés de traitement de maladies associées au hpv
JP7610773B2 (ja) * 2019-02-28 2025-01-09 ステムセル テクノロジーズ カナダ インコーポレーテッド 免疫応答を改変するためのｐｂｍｃへの生体分子の送達
KR20210149791A (ko) 2019-04-08 2021-12-09 에스큐지 바이오테크놀로지스 컴퍼니 페이로드를 세포 내로 전달하기 위한 시스템에서 이용하기 위한 카트리지
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CA3177288A1 (en) * 2020-05-11 2021-11-18 F.Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
WO2022051437A2 (en) * 2020-09-02 2022-03-10 Sqz Biotechnologies Company Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells
WO2022147026A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company METHODS FOR TREATING CANCERS WITH MODIFIED PBMCs
CN116847880A (zh) 2020-12-29 2023-10-03 Sqz生物技术公司 活化抗原载体的调配物
WO2022147017A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations for cryopreservation of pbmcs
JP2024501023A (ja) * 2020-12-29 2024-01-10 スクイーズ バイオテクノロジーズ カンパニー 活性化抗原担体を用いるがんを処置するための方法
US20240182851A1 (en) * 2021-04-02 2024-06-06 Sqz Biotechnologies Company Reprogramming of cells and uses thereof
WO2023003907A1 (en) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
CN118510888A (zh) 2021-11-11 2024-08-16 加拿大干细胞技术公司 通过微流体递送来产生增强的肿瘤浸润性淋巴细胞的方法
CA3262756A1 (en) 2022-07-28 2024-02-01 Stemcell Technologies Canada Inc. CANCER TREATMENT METHODS WITH ENHANCED ANTIGEN-PRESENTING CELLS
EP4561615A2 (en) 2022-07-28 2025-06-04 Stemcell Technologies Canada Inc. Enhanced antigen presenting cell formulations

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502621C3 (de) 1975-01-23 1978-09-14 Kernforschungsanlage Juelich Gmbh, 5170 Juelich Messung elastischer und dielektrischer Eigenschaften der Membran lebender Zellen
US4376634A (en) 1980-05-30 1983-03-15 Mallinckrodt, Inc. Assay kit having syringe, dilution device and reagents within sealed container
FR2569477B1 (fr) 1984-08-24 1987-01-02 Descartes Universite Rene Appareil et procede pour la determination de la deformabilite des globules rouges du sang
JP2720161B2 (ja) 1988-02-01 1998-02-25 株式会社アドバンス 細胞変形能測定装置
JP2685544B2 (ja) 1988-11-11 1997-12-03 株式会社日立製作所 血液フィルタおよび血液検査方法並びに血液検査装置
JP2532707B2 (ja) 1990-03-08 1996-09-11 佑二 菊池 血液回路及びこれを用いた血液測定装置及び血液測定方法
WO2002067863A2 (en) 2001-02-22 2002-09-06 The Scepens Eye Research Institute, Inc. Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
WO2003020039A1 (en) 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
EP1411351A4 (en) 2002-06-05 2010-07-07 Panasonic Corp DEVICE FOR MEASURING THE EXTRACELLULAR POTENTIAL AND METHOD FOR PRODUCING THE DEVICE
US20060134067A1 (en) 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
US20090028874A1 (en) 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US7968335B2 (en) 2004-06-17 2011-06-28 Ken Nakata Cell culturing method using biomechanical stimulation loading and system therefor
ES2350895T3 (es) 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
US20060134772A1 (en) 2004-11-18 2006-06-22 The Regents Of The University Of California System for locating cells and for cellular analysis
US7704743B2 (en) 2005-03-30 2010-04-27 Georgia Tech Research Corporation Electrosonic cell manipulation device and method of use thereof
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US8293524B2 (en) 2006-03-31 2012-10-23 Fluxion Biosciences Inc. Methods and apparatus for the manipulation of particle suspensions and testing thereof
US20070249038A1 (en) 2006-04-21 2007-10-25 Andrea Adamo Microfluidic device for single cell targeted operations
EP2054499A2 (en) 2006-08-17 2009-05-06 Massachusetts Institute of Technology Method and apparatus for microfluidic injection
WO2008098094A1 (en) 2007-02-06 2008-08-14 Network Biosystems, Inc. Devices and methods for the performance of miniaturized in vitro assays
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
GB0718160D0 (en) 2007-09-18 2007-10-24 Medical Res Council Methods
EP2216639A4 (en) 2007-11-28 2014-01-15 Konica Minolta Opto Inc APPARATUS AND METHOD FOR MEASURING BLOOD FLUIDITY
US20090280518A1 (en) 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
JP5137129B2 (ja) 2008-07-23 2013-02-06 国立大学法人山口大学 血液細胞の力学的特性測定装置
US9115340B2 (en) 2008-08-08 2015-08-25 Agency For Science Technology & Research Microfluidic continuous flow device
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US9364831B2 (en) 2009-08-08 2016-06-14 The Regents Of The University Of California Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting
WO2011051346A1 (en) 2009-10-27 2011-05-05 Erytech Pharma Composition to induce specific immune tolerance
AU2010336424B2 (en) 2009-12-23 2013-06-13 Cytovera, Inc. A system and method for particle filtration
US20120064505A1 (en) 2010-03-22 2012-03-15 Massachusetts Institute Of Technology Measurement of material properties and related methods and compositions
ES2869155T3 (es) 2010-11-25 2021-10-25 Imnate Sarl Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
ES2764105T3 (es) 2011-10-17 2020-06-02 Massachusetts Inst Technology Administración intracelular
WO2013185032A1 (en) 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
SG10201801188XA (en) 2013-08-16 2018-03-28 Massachusetts Inst Technology Selective delivery of material to cells
RU2739794C2 (ru) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
JP6846345B2 (ja) 2014-11-14 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー 破壊及び場による細胞への化合物及び組成物の送達
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
AU2016289530B2 (en) 2015-07-09 2021-05-06 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
JP7046795B2 (ja) 2015-09-04 2022-04-04 スクイーズ バイオテクノロジーズ カンパニー 細孔を有する表面によって媒介される生体分子の細胞内送達
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
ES2964746T3 (es) 2015-12-30 2024-04-09 Celgene Corp Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo
CN108779475A (zh) 2016-01-12 2018-11-09 Sqz生物技术公司 复合物的细胞内递送
RU2770492C2 (ru) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биологических молекул для индуцирования толерантности
RU2747878C2 (ru) 2016-05-03 2021-05-17 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биомолекул для индукции толерантности
US11422127B2 (en) * 2016-12-07 2022-08-23 Albany Medical College Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
JP2021507689A (ja) 2017-12-05 2021-02-25 スクイーズ バイオテクノロジーズ カンパニー 抗体産生をモジュレートするための生体分子の細胞内送達
JP2021506309A (ja) 2017-12-20 2021-02-22 スクイーズ バイオテクノロジーズ カンパニー 細胞の中へのペイロードの送達のためのシステム
JP7595827B2 (ja) 2018-03-12 2024-12-09 ステムセル テクノロジーズ カナダ インコーポレーテッド 免疫応答を改変するための生体分子の細胞内送達
MA52003A (fr) 2018-03-12 2021-01-20 Sqz Biotechnologies Co Procédés de traitement de maladies associées au hpv
US20210388390A1 (en) 2018-10-04 2021-12-16 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
WO2020154696A1 (en) 2019-01-25 2020-07-30 Sqz Biotechnologies Company Anucleate cell-derived vaccines
JP7610773B2 (ja) 2019-02-28 2025-01-09 ステムセル テクノロジーズ カナダ インコーポレーテッド 免疫応答を改変するためのｐｂｍｃへの生体分子の送達
KR20210149791A (ko) 2019-04-08 2021-12-09 에스큐지 바이오테크놀로지스 컴퍼니 페이로드를 세포 내로 전달하기 위한 시스템에서 이용하기 위한 카트리지

Also Published As

Publication number Publication date
CO2021012581A2 (es) 2022-01-17
JP2022522351A (ja) 2022-04-18
US20240228956A9 (en) 2024-07-11
EP3931309A4 (en) 2022-12-21
US20200318066A1 (en) 2020-10-08
KR20210134353A (ko) 2021-11-09
TWI904084B (zh) 2025-11-11
PE20220379A1 (es) 2022-03-18
SG11202109333SA (en) 2021-09-29
TW202045717A (zh) 2020-12-16
AU2020228648A1 (en) 2021-10-14
WO2020176789A1 (en) 2020-09-03
MX2021010320A (es) 2021-11-12
ZA202106308B (en) 2024-12-18
CA3131701A1 (en) 2020-09-03
BR112021016903A2 (pt) 2021-11-03
CN114127267A (zh) 2022-03-01
JP7610773B2 (ja) 2025-01-09
CL2021002258A1 (es) 2022-06-17
IL285809A (en) 2021-10-31
US20240132839A1 (en) 2024-04-25
US11692168B2 (en) 2023-07-04
PH12021500033A1 (en) 2022-06-06
EP3931309A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
ZA202106308B (en) Delivery of biomolecules to pbmcs to modify an immune response
PH12020551436A1 (en) Intracellular delivery of biomolecules to modify immune response
PH12020551437A1 (en) Methods for treating hpv-associated diseases
CL2019002036A1 (es) Anticuerpo contra bcma y su uso.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
ZA202104246B (en) Humanized anti-human-pd-1 antibody
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
PH12020552181A1 (en) Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CY1120976T1 (el) Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων
BR112015023515A8 (pt) construtos de tecido hepático tridimensionais vivos engenheirados, métodos para fabricá-los e uso destes para aumentar uma ou mais funções hepáticas em um ser humano
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
MX2021007845A (es) Anticuerpos contra il-4ra humano y uso de los mismos.
MX2020000369A (es) Metodos biologicos para preparar terpenos.
CR20160570A (es) Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
WO2018120843A9 (zh) 一种三功能分子及其应用
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
MY197793A (en) Solar cells and methods of making the same
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
AR088428A1 (es) Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico